ECSP14024526A - Derivados bicíclicos de pirazinona - Google Patents
Derivados bicíclicos de pirazinonaInfo
- Publication number
- ECSP14024526A ECSP14024526A ECIEPI201424526A ECPI201424526A ECSP14024526A EC SP14024526 A ECSP14024526 A EC SP14024526A EC IEPI201424526 A ECIEPI201424526 A EC IEPI201424526A EC PI201424526 A ECPI201424526 A EC PI201424526A EC SP14024526 A ECSP14024526 A EC SP14024526A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirazinone
- bicyclic derivatives
- diseases
- tankirase
- inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12002215 | 2012-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14024526A true ECSP14024526A (es) | 2015-09-30 |
Family
ID=48013911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201424526A ECSP14024526A (es) | 2012-03-28 | 2014-10-27 | Derivados bicíclicos de pirazinona |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9120805B2 (enExample) |
| EP (1) | EP2831077B1 (enExample) |
| JP (1) | JP6096879B2 (enExample) |
| KR (1) | KR102070567B1 (enExample) |
| CN (1) | CN104169284B (enExample) |
| AR (1) | AR090496A1 (enExample) |
| AU (1) | AU2013242492B2 (enExample) |
| CA (1) | CA2868620C (enExample) |
| CL (1) | CL2014002557A1 (enExample) |
| CO (1) | CO7111292A2 (enExample) |
| DK (1) | DK2831077T3 (enExample) |
| EA (1) | EA027416B1 (enExample) |
| EC (1) | ECSP14024526A (enExample) |
| ES (1) | ES2585044T3 (enExample) |
| HR (1) | HRP20160908T1 (enExample) |
| HU (1) | HUE030067T2 (enExample) |
| IL (1) | IL234713A (enExample) |
| MX (1) | MX351149B (enExample) |
| MY (1) | MY172308A (enExample) |
| NZ (1) | NZ630489A (enExample) |
| PE (1) | PE20142186A1 (enExample) |
| PH (1) | PH12014501829B1 (enExample) |
| PL (1) | PL2831077T3 (enExample) |
| PT (1) | PT2831077T (enExample) |
| RS (1) | RS54997B1 (enExample) |
| SG (1) | SG11201405750YA (enExample) |
| SI (1) | SI2831077T1 (enExample) |
| TW (1) | TWI576346B (enExample) |
| UA (1) | UA112795C2 (enExample) |
| WO (1) | WO2013143663A1 (enExample) |
| ZA (1) | ZA201407828B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| HRP20160908T1 (hr) | 2012-03-28 | 2016-09-23 | Merck Patent Gmbh | Biciklički derivati pirazinona |
| CA2870062A1 (en) * | 2012-06-20 | 2013-12-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| HUE037606T2 (hu) | 2013-12-23 | 2018-09-28 | Merck Patent Gmbh | Imidazopirazinon-származékok |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| KR101739003B1 (ko) * | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| KR20170090476A (ko) | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
| CN107922409A (zh) | 2015-08-17 | 2018-04-17 | 鲁宾有限公司 | 作为parp抑制剂的杂芳基衍生物 |
| MX383747B (es) | 2016-02-24 | 2025-03-14 | Pfizer | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak) |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| SG11202010679SA (en) * | 2018-05-17 | 2020-11-27 | Bayer Ag | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| GB2632307A (en) * | 2023-08-02 | 2025-02-05 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| GB2632441A (en) * | 2023-08-08 | 2025-02-12 | Duke Street Bio Ltd | Deuterated PARP1 inhibitor compounds |
| WO2025084446A1 (ko) * | 2023-10-16 | 2025-04-24 | 에스티팜 주식회사 | 트리아졸로피리미디논 유도체의 결정형 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| JP5271897B2 (ja) * | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
| MX2009007053A (es) * | 2006-12-28 | 2009-07-09 | Abbott Lab | Inhibidores de poli (adp-ribosa) polimerasa. |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| WO2009130231A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists |
| JP5579724B2 (ja) | 2008-10-17 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環 |
| CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
| MX2012012059A (es) * | 2010-04-16 | 2013-03-21 | Abbvie Inc | Inhibidores de pirrolopirazinona de cinasas. |
| CN102229611B (zh) * | 2011-04-26 | 2012-12-12 | 山东大学 | 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用 |
| HRP20160908T1 (hr) | 2012-03-28 | 2016-09-23 | Merck Patent Gmbh | Biciklički derivati pirazinona |
| CA2870062A1 (en) * | 2012-06-20 | 2013-12-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
-
2013
- 2013-03-19 HR HRP20160908TT patent/HRP20160908T1/hr unknown
- 2013-03-19 UA UAA201411566A patent/UA112795C2/uk unknown
- 2013-03-19 SI SI201330254A patent/SI2831077T1/sl unknown
- 2013-03-19 EA EA201401062A patent/EA027416B1/ru not_active IP Right Cessation
- 2013-03-19 HU HUE13712685A patent/HUE030067T2/en unknown
- 2013-03-19 NZ NZ630489A patent/NZ630489A/en not_active IP Right Cessation
- 2013-03-19 WO PCT/EP2013/000827 patent/WO2013143663A1/en not_active Ceased
- 2013-03-19 JP JP2015502129A patent/JP6096879B2/ja active Active
- 2013-03-19 CN CN201380017205.4A patent/CN104169284B/zh active Active
- 2013-03-19 ES ES13712685.0T patent/ES2585044T3/es active Active
- 2013-03-19 KR KR1020147029895A patent/KR102070567B1/ko not_active Expired - Fee Related
- 2013-03-19 CA CA2868620A patent/CA2868620C/en active Active
- 2013-03-19 PE PE2014001502A patent/PE20142186A1/es active IP Right Grant
- 2013-03-19 SG SG11201405750YA patent/SG11201405750YA/en unknown
- 2013-03-19 PT PT137126850T patent/PT2831077T/pt unknown
- 2013-03-19 RS RS20160596A patent/RS54997B1/sr unknown
- 2013-03-19 EP EP13712685.0A patent/EP2831077B1/en active Active
- 2013-03-19 PL PL13712685.0T patent/PL2831077T3/pl unknown
- 2013-03-19 MX MX2014011420A patent/MX351149B/es active IP Right Grant
- 2013-03-19 DK DK13712685.0T patent/DK2831077T3/en active
- 2013-03-19 MY MYPI2014702730A patent/MY172308A/en unknown
- 2013-03-19 US US14/388,270 patent/US9120805B2/en active Active
- 2013-03-19 AU AU2013242492A patent/AU2013242492B2/en active Active
- 2013-03-26 AR ARP130100972A patent/AR090496A1/es active IP Right Grant
- 2013-03-27 TW TW102110996A patent/TWI576346B/zh not_active IP Right Cessation
-
2014
- 2014-08-13 PH PH12014501829A patent/PH12014501829B1/en unknown
- 2014-08-20 CO CO14182299A patent/CO7111292A2/es unknown
- 2014-09-18 IL IL234713A patent/IL234713A/en active IP Right Grant
- 2014-09-25 CL CL2014002557A patent/CL2014002557A1/es unknown
- 2014-10-27 EC ECIEPI201424526A patent/ECSP14024526A/es unknown
- 2014-10-27 ZA ZA2014/07828A patent/ZA201407828B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| CL2017000290A1 (es) | Inhibidores de la proteína kinasa c y métodos de su uso. | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CO6781507A2 (es) | Novedosos derivados heterociclicos | |
| UY35142A (es) | Derivados de triazolopirazinas como inhibidores de brd4 | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| MX2016001136A (es) | Derivados de oxoquinazolinil-butanamida. | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| BR112016001978A2 (pt) | derivados de ciclopentano 1,3-dissubstituído | |
| IL239035B (en) | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors | |
| AR090085A1 (es) | USO DE COMPUESTOS DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE GLUCOGENO SINTASA CINASA 3 b | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |